KDAGF (KDA Group) ROE % Adjusted to Book Value: -11.46% (As of Jan. 2026)


What is KDA Group ROE % Adjusted to Book Value?

KDA Group KDAGF ROE % Adjusted to Book Value is -11.46% as of Jan. 2026. The stock has 3 warning signs investors should review.

KDA Group's ROE % for the quarter that ended in Jan. 2026 was -57.29%. KDA Group's PB Ratio for the quarter that ended in Jan. 2026 was 5.00. KDA Group's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2026 was -11.46%.

KDA Group ROE % Adjusted to Book Value Related Terms

KDA Group ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for KDA Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KDA Group ROE % Adjusted to Book Value Chart

KDA Group Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -11.18 -14.19

KDA Group Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.31 -14.86 -18.19 -10.90 -11.46

KDAGF vs VEEV, BTSG, TEM: ROE % Adjusted to Book Value Comparison

For the Health Information Services subindustry, KDA Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KDA Group ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, KDA Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where KDA Group's ROE % Adjusted to Book Value falls into.


KDA Group ROE % Adjusted to Book Value Calculation

KDA Group's ROE % Adjusted to Book Value for the fiscal year that ended in Jul. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-68.96% / 4.86
=-14.19%

KDA Group's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-57.29% / 5.00
=-11.46%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -11.46% mean?
KDA Group (KDAGF) has a ROE % Adjusted to Book Value of -11.46% as of Jan. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on KDA Group and its competitors.
Is KDA Group's ROE % Adjusted to Book Value too high?
KDA Group's current ROE % Adjusted to Book Value is -11.46%.
How does KDA Group's ROE % Adjusted to Book Value compare to VEEV and BTSG?
KDA Group's ROE % Adjusted to Book Value of -11.46% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on KDA Group and its competitors. KDA Group's current ROE % Adjusted to Book Value is -11.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KDA Group stock overvalued right now?
KDA Group (KDAGF) has a current ROE % Adjusted to Book Value of -11.46%. The current ROE % Adjusted to Book Value is -11.46%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For KDA Group (KDAGF), the current ROE % Adjusted to Book Value is -11.46% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

KDA Group Business Description

Other Exchanges O1M:GermanyKDA:Canada
Address 1351 Notre-Dame East, Suite 300, Thetford Mines, QC, CAN, G6G 0G5
KDA Group Inc provides technological and operational efficiency solutions for general and specialized health sectors through its technology platform, which includes electronic prescription platforms for Canada and the United States and Adherize and Medherize functionalities for pharmaceutical adherence and oncology-focused therapeutic monitoring. The company operates through two segments: Pharmaceutical Technology and Corporate.